TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMO stock, giving a Buy rating on August 8.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given her Buy rating due to a combination of factors that highlight Sangamo Biosciences’ strategic positioning and potential for growth. The company is actively engaging in partnership discussions for its Phase 1/2 ‘920 program in Fabry disease and is preparing for a Biologics License Application (BLA) submission for its gene therapy in Hemophilia A. These developments indicate a clear regulatory pathway and potential market opportunities.
Additionally, Sangamo’s financial management appears robust, with a pro forma cash estimate of approximately $29 million expected to support operations into the fourth quarter of 2025. The company’s recent collaboration with Eli Lilly, which resulted in a significant upfront payment, further strengthens its financial position. The strategic focus on advancing its pipeline, coupled with effective cost management, supports the positive outlook and Buy rating from Ritu Baral.
In another report released on August 8, Barclays also maintained a Buy rating on the stock with a $5.00 price target.